Feasibility of the nutritional intervention is assessed by change in MM as a surrogate marker.
Changes to skeletal MM, physical function, anthropometrics, body composition, muscle strength, physical activity, energy metabolism, metabolic markers, nutritional status, quality of life, readiness to change and psychosocial determinants of behavioural change are assessed between the HP and NP groups. Assessments are completed within two weeks of starting chemotherapy (baseline), at week 6, and at week 12.
Energy recommendations are based on measured energy expenditure. These values refer to the upper and lower recommended range of protein intake for people with cancer. The HP and NP groups receive nutrition recommendations to achieve 2.0 g of protein per kilogram of body weight per day (g∙kg −1∙d −1) and 1.0 g⋅kg −1⋅d −1, respectively. Participants are randomly assigned to a HP or normal protein (NP) diet for twelve weeks. Forty patients with newly diagnosed stage II-IV colorectal cancer who are scheduled to receive chemotherapy will be included.
#Oxygen not included download 210489 trial
The Protein Recommendation to Increase Muscle (PRIMe) study is a single-center, two-armed, parallel, randomized, controlled pilot trial that assesses the feasibility of utilizing a high protein (HP) diet to positively impact clinical outcomes in people undergoing chemotherapy to treat colorectal cancer.
0 kommentar(er)
